Acrivon Therapeutics Reports 2024 Financial Results and Progress

An announcement from Acrivon Therapeutics, Inc. ( (ACRV) ) is now available.

On March 27, 2025, Acrivon Therapeutics announced its financial results for the fourth quarter and full year 2024, highlighting significant progress in its clinical programs. The company reported promising data from its ACR-368 trials for endometrial cancer, showing a high response rate in heavily pretreated patients, and prioritized this cancer type due to limited treatment options and commercial potential. Additionally, the Phase 1 trial of ACR-2316 is ahead of schedule, with early signs of clinical activity. Acrivon has extended its cash runway into 2027, allowing continued focus on its AP3 platform and drug development efforts.

More about Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc. is a clinical-stage precision medicine company that utilizes its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates. The company focuses on creating treatments that are mechanistically matched to patients whose diseases are predicted to be sensitive to specific therapies.

YTD Price Performance: -54.13%

Average Trading Volume: 80,488

Technical Sentiment Signal: Buy

Current Market Cap: $81.27M

For detailed information about ACRV stock, go to TipRanks’ Stock Analysis page.